Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
Lenacapavir is a groundbreaking, long-acting antiretroviral capsid inhibitor developed by Gilead Sciences to treat and prevent HIV-1 infection. Characterized by Science as the "Breakthrough of the Year", it represents a massive paradigm shift in healthcare because it is administered as a subcutaneous injection only twice a year (every six months) rather than requiring a daily oral pill.
Lenacapavir is a groundbreaking, long-acting antiretroviral capsid inhibitor developed by Gilead Sciences to treat and prevent HIV-1 infection. Characterized by Science as the "Breakthrough of the Year", it represents a massive paradigm shift in healthcare because it is administered as a subcutaneous injection only twice a year (every six months) rather than requiring a daily oral pill.